Opinion|Videos|May 9, 2025
Final Thoughts Alzheimer Disease Care
Panelists discuss how the current Alzheimer disease treatment landscape represents both significant progress with novel amyloid-targeting therapies and ongoing challenges, while expressing hope for future advances including more potent disease-modifying treatments, combination therapies, earlier intervention capabilities, improved biomarkers, greater health care equity, and comprehensive care models that address both medical and psychosocial aspects of the disease.
Advertisement
Video content above is prompted by the following:
- What strategies can clinicians and health systems use to navigate coverage challenges and ensure eligible patients receive timely treatment?
- How does the limited number of neurologists in the United States impact patient care?
- What could be done to help address this shortage? (For example: Could advanced practice providers help fill this gap, and what would be needed to prepare them for this role?)
Advertisement
Related to this article
Merck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
The FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.
The FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About Diabetes-Related Eye Disease Awareness Month
2
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
No Surprises Act Arbitration Added $8.39B in 2025 Plan Obligations
5